The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 130, Issue 2, 2007, Pages 249-257

  Sun, Peng Ming ^a,b,c   Wei, Li Hui ^a   Luo, Mei Yu ^c   Liu, Guang ^c   Wang, Jiang Liu ^a   Mustea, Alexander ^b   Könsgen, Dominique ^b   Lichtenegger, Werner ^b   Sehouli, Jaild ^b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Fujian Provincial Maternity and Child Health Hospital   (China)

Author keywords

Apoptosis; Biomarker; hTERT mRNA; Ovarian cancers; Telomearase activity

Indexed keywords

CISPLATIN; INDICATOR; MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL STRAIN HO 8910; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HTERT GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TELOMERIC REPEAT AMPLIFICATION PROTOCOL;

EID: 33846194672     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2006.01.028     Document Type: Article

References (28)

1. Greenlee R.T., Murray T., Bolden S., and Wingo P.A. Cancer statistics. CA Cancer J Clin 50 (2000) 7-23
2. Sehouli J., Akdogen Z., Heinze T., et al. Preoperativt determination of CASA and CA-125 for the discrimination between benign and malignant pelevic tumor mass: a prospective study. Anticancer Res 23 (2003) 1115-1118
3. Greider C.W., and Blackburn E.H. Identification of a specific telomere terminal transferase activity in Tetrehymena extracts. Cell 43 (1985) 405-413
4. Blackburn E.H. Structure and function of telomeres. Nature 350 (1991) 569-573
5. Morin G.B. The human telomere terminal tranferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59 (1989) 521-529
6. Kim N.W., Piatyszek M.A., Prowse K.R., et al. Specification of human telomerase activity with immortal cells and cancer. Science 266 (1994) 2011-2015
7. Bodnar A.G., Ouellette M., Frolkis M., et al. Extension of life-span by introduction of telomerase into normal human cells. Science 277 (1998) 349-352
8. Counter C.M., Hirte H.W., Bacchetti S., and Harley C.B. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA 91 (1994) 2900-2904
9. Shay J.W., and Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 33 (1997) 787-791
10. Takakura M., Kyo S., Kanaya T., Tanaka M., and Inoue M. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res 58 (1998) 1558-1561
11. Feng J., Funk W.D., Wang S.S., et al. The RNA component of human telomerase. Science 269 (1995) 1236-1241
12. Harrington L., Mcphail T., Mar V., et al. A mammalian telomerase-associated protein. Science 275 (1997) 973-977
13. Meyerson M., Counter C.M., Eaton E.N., et al. hERT2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90 (1997) 785-795
14. Nakamura T.M., Morin G.B., Chapman K.B., et al. The telomerase catalytic subunit homologs from fission yeast and human. Science 277 (1997) 955-959
15. Zhu G., Saed M.G., Deppe G., Diamond P.M., and Munkarah R.A. Hypoxia up-regulates the effects of prostaglandin E2 on tumor angiogenesis in ovarian cancer cells. Gynecol Oncol 94 (2004) 422-426
16. Hiyama E., Gollahon L., Kataoka T., et al. Telomerase activity in human breast tumors. J Natl Cancer Inst 88 (1996) 112-116
17. Kyo S., Kanaya T., Takakura M., et al. Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors. Int J Cancer 80 (1999) 804-809
18. Takahashi M., Kigawa J., Oishi T., et al. Alteration of telomerase activity in ovarian cancer after chemotherapy. Gynecol Obstet Invest 49 (2000) 204-208
19. Kunifuji Y., Gotoh S., Abe T., Miura M., and Karasaki Y. Down-regulation of telomerase activity by anticancer drugs in human ovarian cancer cells. Anti-Cancer Drugs 13 (2002) 595-598
20. Oishi T., Kigawa J., Minagawa Y., et al. Alteration of telomerase activity associated with development and extension of epithelial ovarian cancer. Obstet Gynecol 91 (1998) 568-571
21. Park K.H., Rha S.Y., Kim C.H., et al. Telomerase activity and telomere length in various cell lines: changes of telomerase activity can be another method for chemosensitivity evaluation. In J Oncol 13 (1998) 489-495
22. Takakura M., Kyo S., Kanaya T., et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cell lines. Cancer Res 59 (1999) 551-557
23. Biroccio A., Gabellini C., Amodei S., et al. Telomere dysfunction increase cisplatin and ecteinascidin-743 sensitivity of melanoma cells. Mol Pharmacol 63 (2003) 632-638
24. Furuta M., Nozawa K., Takemura M., et al. A novel platinum compound inhibits telomerase activity in vitro and reduces telomere length in a human hepatoma cell line. Int J Cancer 104 (2003) 709-715
25. Cressey T.R., Tilby M.J., and Newell D.r. Decreased telomerase activity is not a reliable indicator of chemosensitivity in testicular cancer cell lines. Eur J Cancer 38 (2002) 586-593
26. Sanz-Casla T.M., Vidaurreta M., Sanchez-Rueda D., et al. Telomerase activity as prognostic factor in colorectal cancer. Onkologie 28 (2005) 553-557
27. Nouriani M., Bahador A., Berek J.S., et al. Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy. Clinical Cancer Res 10 (2004) 2681-2684
28. Buttitta F., Pellegrini C., Marchetti A., et al. Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. J Clin Oncol 21 (2003) 1320-1325